Trust Company’s AbbVie ABBV Stock Holding History

Trust Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674K	Sell	2,680 -7,614	-74%	-$1.64M	0.06%	88
2026 Q1	$2.24M	Buy	10,294 +390	+4%	+$86.5K	0.21%	50
2025 Q4	$2.26M	Buy	9,904 +7,499	+312%	+$1.71M	0.21%	50
2025 Q3	$557K	Buy	2,405 +281	+13%	+$57.2K	0.06%	82
2025 Q2	$394K	Hold	2,124	–	–	0.04%	99
2025 Q1	$445K	Hold	2,124	–	–	0.05%	98
2024 Q4	$377K	Buy	2,124 +204	+11%	+$37.5K	0.04%	106
2024 Q3	$379K	Buy	1,920 +3	+0.2%	+$560	0.05%	101
2024 Q2	$329K	Hold	1,917	–	–	0.04%	107
2024 Q1	$349K	Hold	1,917	–	–	0.05%	98
2023 Q4	$297K	Sell	1,917 -330	-15%	-$48.1K	0.04%	110
2023 Q3	$335K	Sell	2,247 -128	-5%	-$18.8K	0.05%	100
2023 Q2	$320K	Sell	2,375 -128	-5%	-$18.8K	0.05%	118
2023 Q1	$399K	Sell	2,503 -111	-4%	-$17K	0.06%	104
2022 Q4	$422K	Buy	2,614 +91	+4%	+$14K	0.07%	101
2022 Q3	$339K	Sell	2,523 -177	-7%	-$25.4K	0.07%	99
2022 Q2	$414K	Buy	2,700 +2	+0.1%	+$306	0.09%	92
2022 Q1	$437K	Sell	2,698 -40	-1%	-$5.81K	0.09%	95
2021 Q4	$371K	Sell	2,738 -100	-4%	-$11.8K	0.09%	87
2021 Q3	$306K	Hold	2,838	–	–	0.08%	91
2021 Q2	$320K	Buy	2,838 +85	+3%	+$9.57K	0.22%	85
2021 Q1	$298K	Buy	2,753 +350	+15%	+$37.4K	0.21%	95
2020 Q4	$257K	Buy	2,403 +92	+4%	+$8.84K	0.2%	95
2020 Q3	$202K	Hold	2,311	–	–	0.17%	101
2020 Q2	$227K	Hold	2,311	–	–	0.22%	88
2020 Q1	$176K	Sell	2,311 -440	-16%	-$37.5K	0.19%	76
2019 Q4	$244K	Sell	2,751 -1,000	-27%	-$83K	0.21%	79
2019 Q3	$284K	Buy	3,751 +100	+3%	+$6.86K	0.27%	70
2019 Q2	$266K	Hold	3,651	–	–	0.24%	71
2019 Q1	$294K	Hold	3,651	–	–	0.17%	77
2018 Q4	$337K	Hold	3,651	–	–	0.19%	61
2018 Q3	$345K	Sell	3,651 -135	-4%	-$12.8K	0.16%	59
2018 Q2	$351K	Buy	3,786 +125	+3%	+$12.2K	0.16%	61
2018 Q1	$347K	Buy	3,661 +185	+5%	+$20.3K	0.13%	66
2017 Q4	$336K	Hold	3,476	–	–	0.14%	59
2017 Q3	$309K	Hold	3,476	–	–	0.17%	53
2017 Q2	$252K	Sell	3,476 -150	-4%	-$10.1K	0.12%	78
2017 Q1	$236K	Sell	3,626 -68	-2%	-$4.28K	0.11%	92
2016 Q4	$231K	Sell	3,694 -38,491	-91%	-$2.35M	0.12%	94
2016 Q3	$2.66M	Buy	42,185 +38,559	+1,063%	+$2.5M	1.17%	31
2016 Q2	$224K	Hold	3,626	–	–	0.09%	104
2016 Q1	$207K	Buy	3,626 +995	+38%	+$55.5K	0.09%	103
2015 Q4	$156K	Sell	2,631 -137	-5%	-$7.89K	0.07%	100
2015 Q3	$151K	Buy	2,768 +273	+11%	+$17.8K	0.09%	92
2015 Q2	$168K	Buy	2,495 +1,495	+150%	+$97.6K	0.11%	110
2015 Q1	$59K	Buy	+1,000	New	+$60.4K	0.04%	152

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Trust Company's ABBV Position: Q2 2026 in Review

Trust Company reduced its AbbVie (ABBV) stake by 74% in Q2 2026, selling an estimated $1.64M and leaving 2,680 shares worth $674K. The position accounts for 0.06% of the portfolio, ranked #88.

Trust Company first reported a position in ABBV in Q1 2015 and has held it in 46 quarters since. The position peaked at $2.66M in Q3 2016. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Trust Company held 2,680 shares of AbbVie worth $674K as of Q2 2026.
Trust Company sold 7,614 AbbVie shares in Q2 2026, an estimated $1.64M.
AbbVie made up 0.06% of Trust Company's portfolio in Q2 2026, its #88 holding.
Trust Company first reported a position in AbbVie in Q1 2015 and has held it in 46 quarters since.
Trust Company's AbbVie position peaked at $2.66M in Q3 2016.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.